Alliance for Clinical Trials in Oncology’s Post

For #TrialTuesday, Dr. Haeseong Park, of Dana-Farber Cancer Institute, leads Alliance A022102 to compare the effect of mFOLFIRINOX vs mFOLFOX with or without nivolumab in treating patients with #metastatic HER2 negative #gastroesophageal cancer. To learn more about this trials, visit: https://lnkd.in/g3jFJnRR #NCI #NCTN #gastriccancer

Priv.-Doz. Dr. med. Bastian Czogalla presented data on anti-angiogenic therapy in first-line treatment of low grade serous ovarian cancer - an explorative meta-analysis of the prospective AGO-OVAR 11, 12 and 16 studies #AGOStudiengruppe #AGOStudyGroup #OvarianCancer #LGSOC #ESMO2024

#ICYMI: Eric Miller, MD, PhD, of OSU Comprehensive Cancer Center, leads Alliance A022101/ERASur, a trial for patients with metastatic #colorectalcancer that compares total ablative therapy and usual systemic therapy to usual systemic therapy alone. To learn more about the ERASur trial, visit https://lnkd.in/gQus2pDQ #NCI #NCTN Fight Colorectal Cancer

Dr Guilherme Nader Marta, formerly working at the Jules Bordet Insitute and now at the Dana Farber Cancer Institute unveils findings from the PALLAS trial at SABCS 2023. Analysis reveals HER2-low status does not significantly alter prognosis or palbociclib treatment outcomes in ER+ breast cancer. However, notable geographic variations in HER2-low prevalence highlight the need for precise diagnostics, especially with emerging HER2-targeted therapies. Discover these vital insights. 👇 For all SABCS 2023 videos, find the link in the comments! #SABCS2023 #BreastCancerResearch #HER2Low #OncologyInnovation

🔬 Insights from ASCO 2024! Prof Nabil Saba, MD from Winship Cancer Institute presents the STELLAR-305 trial, a phase 2/3 study evaluating pembrolizumab with zanzalintinib in head and neck cancer. Discover how this combination aims to improve treatment outcomes based on promising data from similar VEGF-TKIs. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #HeadAndNeckCancer #OncologyInnovation #STELLAR305

❓How does sacituzumab #tirumoetcan work as a second- versus third-line therapy for #gastric cancer? 📺 Dr. Jordi Rodón Ahnert of MD Anderson Cancer Center discusses the treatment's use in gastric and #gastroesophageal cancers, and how it was analyzed in the phase 1/2 KL264-01 trial: https://buff.ly/4ag88U0

We're pushing the boundaries in lung cancer research with our hexavalent OX40 agonist, #INBRX106. INBRX-106 is currently being investigated in a phase 1/2 study as a potential treatment option for Non-Small Cell Lung Cancer, including in IO-refractory patients. Learn more about our ongoing study and our commitment to addressing unmet needs: https://bit.ly/49ZyYks #LungCancer #NSCLC #Inhibrx

🔬 Insights from ASCO 2024! Prof christine gennigens from University Hospital Liège presents the SPECTRUM study on HER2 expression in endometrial cancer. This retrospective analysis assesses HER2 low expression rates, their concordance with breast cancer criteria, and their impact on survival outcomes. Discover the implications for treatment with emerging HER2-targeted therapies. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #GynaecologicalCancer #OncologyInnovation #EndometrialCancer

Leading experts offer insights into colorectal cancer, including its prevalence, staging, and the current landscape of treatment options. MD Anderson Cancer Center https://lnkd.in/es43dZ5F #crcsm #cancer #Oncology

🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗜 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟   Exploring the Bright Future of Double Immunochemotherapy in Metastatic Colorectal Cancer: Insights from the CHECKMATE 8WH Trial, Shared by Prof Eric Van Cutsem and Prof Van den Eynde.   👇 Watch all WND GI videos - link in the comments! #MediMix #GastricCancer #Immunotherapy #OncologyResearch